← Product Code [DIO](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DIO) · K101742

# THERMO SCIENTIFIC CEDIA COCAINE OFT ASSAY (K101742)

_Microgenics Corp. · DIO · Apr 8, 2011 · Clinical Toxicology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DIO/K101742

## Device Facts

- **Applicant:** Microgenics Corp.
- **Product Code:** [DIO](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DIO.md)
- **Decision Date:** Apr 8, 2011
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 862.3250
- **Device Class:** Class 2
- **Review Panel:** Clinical Toxicology

## Indications for Use

The CEDIA® Cocaine OFT Assay is intended for use in the qualitative determination of cocaine in human oral fluid at a cutoff concentration of 15 ng/mL in neat oral fluid. The specimen must be collected exclusively with the Oral-Eze™ Saliva Collection System. The assay is calibrated against benzoylecgonine and performed on the MGC240. This in vitro diagnostic device is intended for clinical laboratory use only. The CEDIA Cocaine OFT Assay provides only a preliminary analytical test result. A more specific alternative method must be used to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) are the preferred confirmatory methods. Clinical consideration and professional judgment should be applied to any drug of abuse test result particularly when preliminary positive results are used.

## Device Story

In vitro diagnostic assay for qualitative cocaine detection in human oral fluid; utilizes recombinant DNA technology and bacterial enzyme β-galactosidase; enzyme engineered into inactive fragments (enzyme acceptor and enzyme donor) that reassociate to form active enzyme; competitive immunoassay format; performed on MGC240 clinical chemistry analyzer; requires Oral-Eze™ Saliva Collection System; provides preliminary results for clinical laboratory use; requires confirmation via GC/MS or LC-MS/MS; assists clinicians in drug abuse screening; professional judgment required for interpretation.

## Clinical Evidence

No clinical studies performed. Evidence consists of analytical performance data: precision/reproducibility (N=50/level), cross-reactivity/interference testing, and method comparison studies. Method comparison (n=41 and n=82 samples) against LC-MS/MS showed 100% agreement in one study and 97.6% positive/negative agreement in another. Bench testing only.

## Technological Characteristics

Homogeneous enzyme immunoassay using recombinant DNA technology (US Patent 4708929). Based on bacterial β-galactosidase engineered into inactive enzyme acceptor (EA) and enzyme donor (ED) fragments. Performed on MGC240 analyzer. Requires Oral-Eze™ Saliva Collection System for specimen collection.

## Regulatory Identification

A cocaine and cocaine metabolite test system is a device intended to measure cocaine and a cocaine metabolite (benzoylecgonine) in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of cocaine use or overdose.

## Special Controls

*Classification.* Class II (special controls). A cocaine and cocaine metabolite test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

## Predicate Devices

- OTI Cocaine Metabolite Intercept® MICRO-PLATE EIA ([K001197](/device/K001197.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
k101742

B. Purpose for Submission:
New Device

C. Measurand:
Cocaine in oral fluid

D. Type of Test:
Qualitative immunoassay

E. Applicant:
Microgenics Corporation, Thermo Fisher Scientific Clinical Diagnostic Division

F. Proprietary and Established Names:
CEDIA Cocaine OFT Assay

G. Regulatory Information:

|  Product Code | Classification | Regulation Section | Panel  |
| --- | --- | --- | --- |
|  DIO | Class II | 21 CFR § 862.3250 | 91, Toxicology  |

H. Intended Use:

1. Intended use(s):
See Indications for use below.

{1}

2. Indication(s) for use:

The CEDIA® Cocaine OFT Assay is intended for use in the qualitative determination of cocaine and cocaine metabolites at a cutoff concentration of 15 ng/mL in neat oral fluid. The specimen must be collected exclusively with the Oral-Eze™ Saliva Collection System. The assay is calibrated against benzoylecgonine and performed on the MGC 240. This in vitro diagnostic device is intended for clinical laboratory use only.

The CEDIA® Cocaine OFT Assay provides only a preliminary analytical test result. A more specific alternative method must be used to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) are the preferred confirmatory methods. Clinical consideration and professional judgment should be applied to any drug of abuse test result particularly when preliminary positive results are used.

3. Special conditions for use statement(s):

The CEDIA® Cocaine OFT Assay is for prescription professional use only in clinical chemistry laboratories. It is not for use in Point of Care settings.

4. Special instrument requirements:

MGC 240 analyzer

I. Device Description:

The CEDIA® cocaine OFT Assay uses recombinant DNA technology to produce a homogeneous enzyme immunoassay system. The assay is based on the bacterial enzyme β-galactosidase, which has been genetically engineered into two inactive fragments (enzyme acceptor and enzyme donor). These fragments spontaneously re-associate to form fully active enzyme that cleaves a substrate and then generates a color change that can be measured spectrophotometrically.

The CEDIA® cocaine OFT Assay utilizes the Oral-Eze™ Saliva Collection System consisting of the Oral-Eze™ saliva collector and collection tube with preservative buffer. Oral-Eze™ saliva collector consists of an absorbent pad attached to a plastic handle. The saliva collector is provided with a volume adequacy indicator. The plastic handle has a round window where a blue color will appear when sufficient volume of oral fluid is collected. Samples are collected by placing the collector pad and plastic shield between the lower cheek and gum with the plastic shield facing the cheek. The pad is ejected into the collection tube by placing thumb on the ridges on the handle and pushing the thumb forward. The collection tube is capped and sent to the laboratory for processing and testing.

{2}

J. Substantial Equivalence Information:

1. Predicate device name:
OTI Cocaine Metabolite Intercept ® MICRO-PLATE EIA

2. Predicate 510(k) number:
k001197

3. Comparison with predicate:

|  Comparison | Device - CEDIA® Cocaine OFT Assay | Predicate – k001197
OTI Cocaine Metabolite Intercept ® MICRO-PLATE EIA  |
| --- | --- | --- |
|  Intended Use | Same | The OTI Cocaine Metabolite Intercept® MICRO-PLATE EIA is intended for use by clinical laboratories in the qualitative determination of cocaine and cocaine metabolites in oral fluid collected with the Intercept® Drugs of Abuse (DOA) Oral Specimen Collection Device. For in Vitro Diagnostic Use.  |
|  Measurement Mode | Same | Qualitative measurements only  |
|  Sample Matrix | Same | Oral Fluid  |
|  Calibrator levels | 0, 5.0, 50.0 ng/mL | 0, 5 ng/mL  |
|  Cutoff level | 15 ng/mL in neat oral fluid | 5 ng/mL when oral fluid collected with the Oral Specimen Collection Device  |

3

{3}

4

K. Standard/Guidance Document Referenced (if applicable):

CLSI Documents:

Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline (EP05-A2)

Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline (EP09-A2)

L. Test Principle:

In the assay, analyte in the sample competes with analyte conjugated to one inactive fragment of β-galactosidase for antibody binding site. If analyte is present in the sample, it binds to antibody, leaving the inactive enzyme fragments free to form active enzyme. If analyte is not present in the sample, antibody binds to analyte conjugated on the inactive fragment, inhibiting the reassociation of inactive β-galactosidase fragments, and no active enzyme is formed. The amount of active enzyme formed and resultant absorbance change are directly proportional to the amount of drug present in the sample.

The Oral-Eze Saliva Collection System contains a preservative buffer that dilutes the neat oral fluid sample. The assay result is reported as a positive or negative result relative to the neat oral fluid cutoff of 15 ng/mL.

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Negative neat oral fluid samples were collected into a sample cup. Oral fluid samples were spiked with benzoylecgonine at three times the final concentration into negative neat oral fluid resulting in concentrations at -25%, -50%, -75% below the cutoff, cutoff, and +25%, +50%, +75% and +100% above the cutoff. All spiked neat oral fluid samples (3X) were confirmed by LC-MS/MS. Neat oral fluid samples were applied onto the Oral-EZE collection device pad (n=2 pad/level) until the blue color appeared in the round (sample adequacy) window of the handle. The pads were then ejected into vials containing 2.2 mL of the preservative buffer. All the diluted spiked samples (1X) were then confirmed by LC-MS/MS. Samples were tested using one lot of reagent on three different MGC 240 instruments by three different operators. Five replicates of each sample were tested per run, 2 runs per day for five non-consecutive days, with a total of N=50/level.

{4}

The results are summarized in the following table:

|  Analyte | Tested Concentration (ng/mL) | Cocaine OFT Assay # Neg/# Pos  |
| --- | --- | --- |
|  Benzoylecgonine | 0 | 50 Neg/ 0 Pos  |
|  Benzoylecgonine | -75% | 50 Neg/ 0 Pos  |
|  Benzoylecgonine | -50% | 50 Neg/ 0 Pos  |
|  Benzoylecgonine | -25% | 50 Neg/ 0 Pos  |
|  Benzoylecgonine | Cutoff | 50 Neg/ 0 Pos  |
|  Benzoylecgonine | +25% | 0 Neg/50 Pos  |
|  Benzoylecgonine | +50% | 0 Neg/50 Pos  |
|  Benzoylecgonine | +75% | 0 Neg/50 Pos  |
|  Benzoylecgonine | +100% | 0 Neg/50 Pos  |

b. Linearity/assay reportable range:

Not applicable

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Collection device:

Shipment/Travel Stability:

Oral fluid samples were spiked with benzoylecgonine. Two sets of identical spiked samples were prepared. One set was kept at room temperature in the lab and used as the unshipped control. The other set was tested through three different stress conditions simulating ground shipping, air shipping and various climate conditions (desert, tropical). The shipping temperature should not exceed  $>40^{\circ}\mathrm{C}$ .

Sample Storage and Stability:

The stability of oral fluid samples in the preservative buffer was evaluated in real time. The stability protocol was reviewed and found acceptable. Oral fluid samples can be stored at  $2 - 8^{\circ}\mathrm{C}$  or at room temperature  $(21 - 25^{\circ}\mathrm{C})$  for 21 days.

Reagent Stability:

Real time stability testing was conducted. The stability protocol was reviewed and found acceptable. The testing supports the stability at  $2 - 8^{\circ}\mathrm{C}$  for 24 months. The on board stability of reconstituted reagents is 60 days  $(2 - 8^{\circ}\mathrm{C})$ .

{5}

d. Detection limit:

Sensitivity of this assay is characterized by validating performance around the claimed cutoff concentration of the assay, including a determination of the lowest concentration of drug that is capable of producing a positive result. This information appears in the precision section 1.a., above.

e. Analytical specificity:

Cross-reactivity was established by spiking various concentrations of similarly structured compounds into negative neat oral fluid samples. The concentrations in the neat oral fluid were 3 times the final (1X) tested concentration. These samples were applied onto the pad of the Oral-Eze collection device until the blue color appeared in the round (sample adequacy) window of the handle. The pads were then ejected into the vials containing  $2.2\mathrm{mL}$  of the preservative buffer. The final concentrations of drug in the samples were diluted to 1X concentration. The diluted samples were qualitatively tested and the results were compared to the cutoff calibrator. All compounds were tested in duplicate.

# Specificity and Cross-Reactivity

Cross-reactivity was evaluated by spiking various concentrations (which could be found in a neat oral fluid sample) of structurally related compounds into drug-free neat oral fluid pool, than added to the oral fluid collection device. The various concentrations were evaluated against the cutoff calibrator. The table below lists the concentration of each compound that gave a response approximately equal to the cutoff.

|  Compounds | Tested Concentration in Neat Oral Fluid (ng/mL) | Response Equivalent to the cutoff  |
| --- | --- | --- |
|  Cocaethylene | 180 | Positive  |
|  Cocaine | 180 | Positive  |
|  Ecgonine | 2,550 | Positive  |
|  Ecgonine methyl ester | 34,500 | Negative  |

Various over-the-counter medications and structurally unrelated compounds were tested for cross-reactivity in the assay. Cross-reactant solutions were prepared by adding the compound to neat oral fluid at the concentrations listed in the table below. The neat oral fluid samples were processed using the Oral-Eze device to obtain diluted oral fluid samples which were tested in the CEDIA Cocaine OFT assay. All compounds tested negative and did not show any cross-reactivity.

{6}

|  Compounds | Tested Concentration in Neat Oral Fluid (ng/mL) | Response Equivalent to the cutoff  |
| --- | --- | --- |
|  Acetaminophen | 1,800,000 | Negative  |
|  Acetylsalicylic Acid | 1,800,000 | Negative  |
|  Alprazolam | 30,000 | Negative  |
|  Amobarbital | 30,000 | Negative  |
|  Amoxicillin | 240,000 | Negative  |
|  Amphetamine | 240,000 | Negative  |
|  Ampicillin | 30,000 | Negative  |
|  Atropine | 30,000 | Negative  |
|  β-Phenethylamine | 30,000 | Negative  |
|  Buproprion | 30,000 | Negative  |
|  Butabarbital | 30,000 | Negative  |
|  Butalbital | 30,000 | Negative  |
|  Caffeine | 60,000 | Negative  |
|  Captopril | 1,800,000 | Negative  |
|  Chlordiazepoxide | 240,000 | Negative  |
|  Chlorpromazine | 30,000 | Negative  |
|  Cimetidine | 600,000 | Negative  |
|  Clonazepam | 30,000 | Negative  |
|  Clorazepate | 30,000 | Negative  |
|  Codeine | 120,000 | Negative  |
|  Cotinine | 30,000 | Negative  |
|  Cyclizine | 30,000 | Negative  |
|  Dextromethorphan | 30,000 | Negative  |
|  Diacetylmorphine | 30,000 | Negative  |
|  Diazepam | 120,000 | Negative  |
|  Digoxin | 120,000 | Negative  |
|  Diphenhydramine | 30,000 | Negative  |
|  Enalapril | 120,000 | Negative  |
|  Fluoxetine | 600,000 | Negative  |
|  Gentisic Acid | 30,000 | Negative  |
|  Hydrocodone | 30,000 | Negative  |
|  Ibuprofen | 600,000 | Negative  |
|  Imipramine | 24,000 | Negative  |
|  l-Ephedrine | 30,000 | Negative  |
|  Levothyroxine | 600,000 | Negative  |
|  Lidocaine | 30,000 | Negative  |
|  Loperamide | 30,000 | Negative  |
|  Medazepam | 30,000 | Negative  |
|  Meperidine | 30,000 | Negative  |
|  Methadone | 240,000 | Negative  |
|  Methamphetamine | 240,000 | Negative  |

7

{7}

|  Metoprolol | 30,000 | Negative  |
| --- | --- | --- |
|  Morphine | 60,000 | Negative  |
|  Naproxen | 30,000 | Negative  |
|  Niacinamide | 30,000 | Negative  |
|  Nicotine | 30,000 | Negative  |
|  Nifedipine | 1,500,000 | Negative  |
|  Norchlordiazepoxide | 30,000 | Negative  |
|  Nordiazepam | 30,000 | Negative  |
|  Penicillin | 30,000 | Negative  |
|  Pentobarbital | 30,000 | Negative  |
|  Phencyclidine | 15,000 | Negative  |
|  Phenobarbital | 120,000 | Negative  |
|  Phenylephrine | 30,000 | Negative  |
|  Phenylpropanolamine | 30,000 | Negative  |
|  Procainamide | 30,000 | Negative  |
|  Procaine | 30,000 | Negative  |
|  Propoxyphene | 120,000 | Negative  |
|  Pseudoephedrine | 30,000 | Negative  |
|  Quinidine | 30,000 | Negative  |
|  Ranitidine | 600,000 | Negative  |
|  Salbutamol | 30,000 | Negative  |
|  Salicyluric Acid | 300,000 | Negative  |
|  Secobarbital | 240,000 | Negative  |
|  Temazepam | 30,000 | Negative  |
|  Δ9-THC | 30,000 | Negative  |
|  11-nor-Δ9-THC-COOH | 15,000 | Negative  |
|  Theophyline | 30,000 | Negative  |
|  Tolmetin | 30,000 | Negative  |
|  Verapamil | 600,000 | Negative  |
|  Zomepirac | 30,000 | Negative  |

Potential interference from endogenous and exogenous substances and pH were spiked into neat oral fluid containing benzoylecgonine at $+/- 50\%$ of the cutoff, and then processed through the oral fluid collection device. No interference was observed with the interfering substances and pH 5-9. The results are presented in the table below:

{8}

|  Compounds | Tested Conc. in Neat Oral Fluid (ng/mL) | Cocaine OFT Assay  |   |
| --- | --- | --- | --- |
|   |  | -50% benzoylecgonine | +50% benzoylecgonine  |
|  Cotinine | 0.03 | Negative | Positive  |
|  Nicotine | 0.015 | Negative | Positive  |
|  Hemoglobin | 0.6 | Negative | Positive  |
|  Human serum albumin | 24 | Negative | Positive  |
|  Sodium Chloride | 18 | Negative | Positive  |
|  Cholesterol | 45 | Negative | Positive  |
|  Acetaminophen | 0.3 | Negative | Positive  |
|  Acetylsalicylic Acid | 0.3 | Negative | Positive  |
|  Caffeine | 0.06 | Negative | Positive  |
|  Ibuprofen | 0.12 | Negative | Positive  |
|  Coffee | 6% v/v | Negative | Positive  |
|  Milk | 3% v/v | Negative | Positive  |
|  Orange Juice | 6% v/v | Negative | Positive  |
|  Cranberry Juice | 6% v/v | Negative | Positive  |
|  Soft drink (Coke) | 6% v/v | Negative | Positive  |
|  Toothpaste | 6% v/v | Negative | Positive  |
|  Mouthwash | 6% v/v | Negative | Positive  |
|  Tea | 6% v/v | Negative | Positive  |
|  Denture Adhesive | 6% v/v | Negative | Positive  |
|  Alcohol | 6% v/v | Negative | Positive  |
|  Baking Soda | 6% v/v | Negative | Positive  |
|  Cough Syrup | 6% v/v | Negative | Positive  |
|  Whole Blood | 6% v/v | Negative | Positive  |
|  Hydrogen Peroxide | 6% v/v | Negative | Positive  |
|  pH | 5-9 | Negative | Positive  |

Potential interference from additional food and dental compounds was tested by collecting neat oral fluid from volunteers after use of the following substances: hard candy, chewing gum, chewing tobacco, cigarettes and tooth whitening strips.

{9}

|  Compounds | Tested Concentration in Neat Oral Fluid | Cocaine OFT Assay Results  |   |
| --- | --- | --- | --- |
|   |   |  -50% Cocaine | +50% Cocaine  |
|  Water | n/a | Negative | Positive  |
|  Chewing Tobacco | n/a | Negative | Positive  |
|  Cigarettes | n/a | Negative | Positive  |
|  Gum | n/a | Negative | Positive  |
|  Hard Candy | n/a | Negative | Positive  |
|  Tooth Whitening Strips | n/a | Negative | Positive  |

f. Assay cut-off:

Characterization of how the device performs analytically around the claimed cutoff concentration appears in the precision section, 1.a, above.

2. Comparison studies:

a. Method comparison with predicate device:

Two method comparison studies were performed.

Study 1:

41 unaltered neat oral fluid samples were collected from rehabilitation clinics. The neat oral fluid samples were processed using the Oral-Eze collection device. The diluted samples were tested in the CEDIA Cocaine OFT Assay and compared to the neat and diluted oral fluid samples tested by LC/MS/MS. The results reflect the performance of the entire system including the collection step.

|  Candidate Device Results | Less than half the cutoff concentration by GC/MS analysis | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (greater than 50% above the cutoff concentration)  |
| --- | --- | --- | --- | --- |
|  Positive | 0 | 0 | 2 | 18  |
|  Negative | 19 | 2 | 0 | 0  |

% Agreement among positive and negative is 100%

{10}

LC/MS/MS values used to categorize samples in this table are based on the concentration found in the neat oral fluid sample.

## Study 2:

A total of 82 samples (41 negative and 41 positive) were evaluated by the candidate device and GC/MS. This study was performed on samples already collected with the Oral-Eze Saliva collection device. When the GC/MS values of the diluted samples were compared to the candidate device, the following results were obtained. Therefore the results below do not reflect any inaccuracy inherent in the collection process itself.

Note: this study was performed on samples already collected with the Intercept collection device. When the LC/MS/MS values of the diluted samples were compared to the immunoassay values, the following results were obtained. Therefore the results below do not reflect any inaccuracy inherent in the collection process itself.

|  Candidate Device Results | Negative | Less than half the cutoff concentration by GC/MS analysis | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (greater than 50% above the cutoff concentration)  |
| --- | --- | --- | --- | --- | --- |
|  Positive | 0 | 0 | 1 | 4 | 36  |
|  Negative | 32 | 4 | 4 | 1 | 0  |

% Agreement among positives is 97.6% (40/41)
% Agreement among negatives is 97.6% (40/41)

Discordant sample:

|  Discordant Sample # | OFT assay (POS/NEG) | Neat Sample LC/MS value (ng/mL)  |
| --- | --- | --- |
|  29 | Negative | 18.9  |
|  80 | Positive | 9.0  |

b. Matrix comparison:

Not Applicable

3. Clinical studies:

a. Clinical Sensitivity:

Not Applicable

{11}

b. Clinical specificity:
Not Applicable

c. Other clinical supportive data (when a. and b. are not applicable):
Not Applicable

4. Clinical cut-off:
Not Applicable

5. Expected values/Reference range:
Not Applicable

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

12

---

**Source:** [https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DIO/K101742](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DIO/K101742)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com